“The drug for a serious lung disease, created by artificial intelligence, demonstrated the first signs of efficiency. This was reported by the biotechnology company Insilico Medicine, writes Bloomberg. According to the company, this is the first time when the “generated” AI drug has undergone an intermediate stage of clinical trials. The drug called Rentozertib (Rentoserib) showed improvement of lung function in a small group of patients with idiopathic pulmonary fibrosis. Analysis […]”, – WRITE: Businessua.com.ua
The drug for a serious lung disease, created by artificial intelligence, demonstrated the first signs of efficiency. This was reported by the biotechnology company Insilico Medicine, writes Bloomberg.
According to the company, this is the first time when the “generated” AI drug has undergone an intermediate stage of clinical trials.
A drug called Rentozerb (Rentoserb) showed an improvement in lung function in a small group of patients with idiopathic pulmonary fibrosis. The analysis of biomarkers confirmed that the drug is effective according to the algorithm laid by the AI: reduces the level of protein, which the model associated with the development of the disease.
The company prepares an extended test program to confirm the effectiveness of the drug and intends to receive feedback from regulators and potential partners in the pharmaceutical industry.
The collected data will be the basis for more than 30 other Insilico projects and will help improve the SI model.
The study lasted 12 weeks and covered 71 patients from China. Part of the participants had a deterioration of the condition or problem with the liver.
We will remind, FDA reported the launch of its own AI Elsa to optimize the work of the department.
The gun
Please wait …